Hexagon Capital Partners’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-129
| Closed | -$8.2K | – | 767 |
|
|
2025
Q1 | $8.2K | Sell |
129
-6
| -4% | -$381 | ﹤0.01% | 1031 |
|
|
2024
Q4 | $10.5K | Buy |
135
+1
| +0.7% | +$78 | ﹤0.01% | 996 |
|
|
2024
Q3 | $10.8K | Buy |
134
+58
| +76% | +$4.66K | ﹤0.01% | 895 |
|
|
2024
Q2 | $6.29K | Buy |
76
+22
| +41% | +$1.82K | ﹤0.01% | 965 |
|
|
2024
Q1 | $4.61K | Buy |
54
+50
| +1,250% | +$4.27K | ﹤0.01% | 1011 |
|
|
2023
Q4 | $343 | Sell |
4
-69
| -95% | -$5.92K | ﹤0.01% | 1324 |
|
|
2023
Q3 | $6.54K | Sell |
73
-104
| -59% | -$9.32K | ﹤0.01% | 847 |
|
|
2023
Q2 | $15.1K | Buy |
177
+54
| +44% | +$4.6K | ﹤0.01% | 638 |
|
|
2023
Q1 | $10.2K | Sell |
123
-30
| -20% | -$2.48K | ﹤0.01% | 724 |
|
|
2022
Q4 | $12K | Buy |
153
+16
| +12% | +$1.26K | ﹤0.01% | 675 |
|
|
2022
Q3 | $10K | Buy |
+137
| New | +$10K | ﹤0.01% | 769 |
|